Search

 
Start a new search




Results 1-10 of 10.
  • previous
  • 1
  • next
 |   | 
JRC N°Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)
JRC933312014α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myelomaTEILUF K; SEIDL C.; BLECHERT B.; GAERTNER F. C.; GILBERTZ K.-P.; FERNANDEZ V; BASSERMANN F; ENDELL J; BOXHAMMER R; LECLAIR Stephane; VALLON M.; AICHLER M; FEUCHTINGER A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.
JRC886702014Treatment of bladder cancer with Bi-213-anti-EGFR-MAb – a pilot studySCHEIDHAUER Klemens; SEIDL C.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; AUTENRIETH Michael; KURTZ F; ESSLER M.; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.
JRC831802014213Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cellsPICKHARD Anja; PIONTEK Guido; SEIDL C.; KOPPING Samuel; BLECHERT B.; MISSLBECK Martin; BROCKHOFF Gero; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.
JRC737802013Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenationWULBRAND Christian; SEIDL C.; GAERTNER F. C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.; SENEKOWITSCH-SCHMIDTKE R.
JRC804852013Die Alpha-Emitter Radioimmuntherapie des multiplen Myeloms mit 213Bi-CHX-A“-DTPA-anti-CD38 Immunkonjugaten zeigt eine hohe Effizienz im präklinischen Xenograft-ModellTEILUF K; SEIDL C.; BLECHERT B.; GÄRTNER Florian; GILBERTZ K.-P.; FERNANDEZ V; BASSERMANN F; ENDELL J; BOXHAMMER R; AICHLER M; FEUCHTINGER A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.
JRC795752013Treatment of Bladder Cancer with Bi-213-anti-EGFR Immunoconjugates in a Nude Mouse ModelSEIDL C.; PFOST B.; MÜLLER Felix; RÖTZER S; FAZEL J; GILBERTZ K.-P.; FEUCHTINGER A; WEIRICH G; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; AUTENRIETH M.; ESSLER M.; SENEKOWITSCH-SCHMIDTKE R.
JRC765832012Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrestVALLON M.; SEIDL C.; BLECHERT B.; LI Zhoulei; GILBERTZ K.-P.; BAUMGART Anja; AICHLER M; FEUCHTINGER A; GAERTNER F. C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; WALCH Axel K.; SENEKOWITSCH-SCHMIDTKE R.; ESSLER M.
JRC717132012Combined 213Bi-DTPA- F3 and paclitaxel treatment of peritoneal spread of human ovarian carcinoma in a mouse model enhances therapeutic efficacy due to enhanced induction of apoptosis and G2/M phase cell-cycle arrestSEIDL C.; VALLON M.; BLECHERT B.; GILBERTZ K.-P.; AICHLER M; FEUCHTINGER A; GÄRTNER Florian; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.
JRC702962012Radiopeptidtherapie des Ovarialkarzinoms mit Alphastrahlern: Verbesserte Tumorkontrolle durch Kombination von 213Bi-DTPA-F3 mit Taxol bei irreversiblen Zellzyklusarrest von Ovarialkarzinomzellen in der G2/M-PhaseSEIDL C.; VALLON M.; BLECHERT B.; GÄRTNER Florian; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.
JRC680422012Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosisESSLER M.; GAERTNER F. C.; NEFF Frauke; BLECHERT B.; SENEKOWITSCH-SCHMIDTKE R.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SEIDL C.
Results 1-10 of 10.
  • previous
  • 1
  • next

Discover